Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019

Autor: Julie M. Crawford, Robert S. Brown, K. Rajender Reddy, Andrea R. Mospan, Elizabeth C. Verna, Michael W. Fried, Janet S. Hildebrand, Breda Munoz, Charles S. Landis, Heather L Morris

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background Patients hospitalized for coronavirus disease 2019 (COVID-19) may experience complications following hospitalization and require readmission. In this analysis, we estimated the rate and risk factors associated with COVID-19–related readm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12cafc2875961c6db91d69957e22c48
https://doi.org/10.1093/cid/ciab464

Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C

Autor: Jian Zhang, Grace Lai-Hung Wong, Michael H. Le, Mindie H. Nguyen, An Le, Charles S. Landis, Mike T. Wei, Ramsey Cheung, Huy N. Trinh

Publikováno v: Journal of medical virologyREFERENCES. 93(11)

Currently, there is no well-established algorithm predicting hepatocellular carcinoma (HCC) development in untreated hepatitis C virus (HCV) patients. We aimed to validate an algorithm (risk evaluation of viral load elevation and associated liver dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac77977e08c45351f9134bf636fb8dec
https://pubmed.ncbi.nlm.nih.gov/34219250

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Autor: Bilal Hameed, Simon M. Rushbrook, Andrew J. Muir, Stephen H. Caldwell, G. Mani Subramanian, Jun Xu, Michael Trauner, Georgia Li, Bertus Eksteen, Chuhan Chung, Mitchell L. Shiffman, Xiaomin Lu, Charles S. Landis, Jen Chieh Chuang, Kris V. Kowdley, Aliya Gulamhusein, Kosh Agarwal, Andrew N. Billin, Christopher L. Bowlus, Robert P. Myers

Publikováno v: Hepatology (Baltimore, Md.), vol 70, iss 3
Hepatology (Baltimore, Md.)

Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e92a15a9c78f04557c3d88c3492d5c
https://doi.org/10.1002/hep.30509

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Autor: Fernando Membreno, Giuseppe Morelli, Ray Thomason, Kalyan Ram Bhamidimarri, Dawn Torres, Andrew Scanga, Danielle Brandman, Guy W. Neff, Mark McKenzie, Stephen H. Caldwell, Kathleen E. Corey, Nadeem Anwar, Kimberly A. Brown, James Strobel, Sammy Saab, Thomas Amankonah, Bal R. Bhandari, Souvik Sarkar, Don C. Rockey, Miguel Á. Rodríguez, Mazen Noureddin, Edward Mena, Nikolaos Pyrsopoulos, Ayman Koteish, Gary A. Abrams, Andrew DeLemos, Richard Frederick, Bhaktasharan Patel, David T. Hagerty, Amy Stratton, Kathryn J. Lucas, Ethan M. Weinberg, Zeid Kayali, Anita Kohli, Marina Roytman, Kris V. Kowdley, Nicole Wedick, Brett E. Fortune, Michael P. Curry, Sofia Jakab, Kiran Bambha, Satinder Gill, Stevan A. Gonzalez, Nikunj Shah, Warren N. Schmidt, Jean L. Chan, Charles S. Landis, Bradley Freilich, Catherine Frenette, Hugo E. Vargas, Mary E. Rinella, Mohammad S. Siddiqui, Andrew P. Keaveny, George Therapondos, Elizabeth C. Verna, Ray Kim, James M. Robinson, David I. Bernstein, Marwan Ghabril, Reem Ghalib, John M. Vierling, Manal F. Abdelmalek, Paul J. Thuluvath, Jen-Jung Pan, Ravi Ravendhran, Amanda Wieland, Eric Lawitz, Justin Reynolds, Victor Ankoma-Sey, Mitchell L. Shiffman, Nyingi Kemmer, William M. Lee, Viviana Figueroa-Diaz, Douglas A. Simonetto, Jonathan Huang, Aasim Sheikh, Parvez S. Mantry, Harvey Tatum, Lance Stein

Publikováno v: Journal of hepatology. 74(2)

Background & Aims Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76272acaeb30d8a655a783c8511b9b83
https://pubmed.ncbi.nlm.nih.gov/33038432

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Autor: Michael W. Fried, Stuart C. Gordon, Fred Poordad, Robert Reindollar, Ran Liu, Charles S. Landis, Federico J. Mensa, Armen Asatryan, David E. Bernstein, Mark S. Sulkowski, Teresa I. Ng, Jens Kort, Franco Felizarta, Sandra S. Lovell, C.-W. Lin, Steven L. Flamm

Publikováno v: Hepatology (Baltimore, Md.)

Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258311f6270e7d670311483f16c48411
https://doi.org/10.1002/hep.29081